Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, International, Multicenter, Randomised Open Label Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Patients With Childhood Onset Idiopathic Nephrotic Syndrome

NCT05627557 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT05627557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05627557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, International, Multicenter, Randomised Open Label Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Patients With Childhood Onset Idiopathic Nephrotic Syndrome
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
March 29, 2023
Completion date
August 27, 2026
Enrollment
85 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

childhood idiopathic nephrotic syndrome